Journal Home > Volume 6 , Issue 1
Journal of Neurorestoratology 2018, 6(1): 67-73 https://doi.org/10.26599/JNR.2018.9040001
Review Article | Open Access | Issue | Published: 29 June 2018

2017 Yearbook of Neurorestoratology

Show Author's Information Hongyun Huang1,2,  Stephen Skaper3,  Gengsheng Mao1,  Hooshang Saberi4,  Shiqing Feng5,  Sang Ryong Jeon6,  Lin Chen2,7,  Milan Dimitrijevic8
Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing 100039, China
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing 100043, China
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
Department of Neurosurgery, Brain and Spinal Injury Research center, Tehran University of Medical Sciences, Tehran, Iran
Department of Orthopaedics, Tianjin Medical University General Hospital, Tianjin, China
Department of Neurosurgery, Department of Neurological Surgery, ASAN Medical Center University of Ulsan College of Medicine, Seoul, Republic of Korea
Department of Neurosurgery, Tsinghua University Yuquan Hospital, Beijing, China
Baylor College of Medicine, Houston, TX, USA
Keywords:
neurorestoratology, Yearbook, pathogenesis, diseases and damage to the nervous system, neurorestorative mechanisms, neurorestorative therapies
Cite this article:
Huang H, Skaper S, Mao G, et al. 2017 Yearbook of Neurorestoratology. Journal of Neurorestoratology, 2018, 6(1): 67-73. https://doi.org/10.26599/JNR.2018.9040001
Download citation
EndNote(RIS)
BibTeX

471

Views

17

Downloads

Citations

5

Crossref

6

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

In 2016 we published the first Yearbook of Neurorestoratology, which summarized pathogenesis in nervous system disease and damage, as well as neurorestorative mechanisms and neurorestorative therapeutic results. Given the progress and achievements occurring in 2017, we have put together those major progresses as the “2017 Yearbook of Neurorestoratology”, which can help readers to easily follow the latest developments in Neurorestoratology.


menu
Abstract
Full text
Outline
About this article

2017 Yearbook of Neurorestoratology

Show Author's information Hongyun Huang1,2, Stephen Skaper3, Gengsheng Mao1, Hooshang Saberi4, Shiqing Feng5, Sang Ryong Jeon6, Lin Chen2,7, Milan Dimitrijevic8
Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing 100039, China
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing 100043, China
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
Department of Neurosurgery, Brain and Spinal Injury Research center, Tehran University of Medical Sciences, Tehran, Iran
Department of Orthopaedics, Tianjin Medical University General Hospital, Tianjin, China
Department of Neurosurgery, Department of Neurological Surgery, ASAN Medical Center University of Ulsan College of Medicine, Seoul, Republic of Korea
Department of Neurosurgery, Tsinghua University Yuquan Hospital, Beijing, China
Baylor College of Medicine, Houston, TX, USA

Abstract

In 2016 we published the first Yearbook of Neurorestoratology, which summarized pathogenesis in nervous system disease and damage, as well as neurorestorative mechanisms and neurorestorative therapeutic results. Given the progress and achievements occurring in 2017, we have put together those major progresses as the “2017 Yearbook of Neurorestoratology”, which can help readers to easily follow the latest developments in Neurorestoratology.

Keywords: neurorestoratology, Yearbook, pathogenesis, diseases and damage to the nervous system, neurorestorative mechanisms, neurorestorative therapies

References(69)

[1]
Huang H, Mao G, Feng S, et al. 2016 yearbook of neurorestoratology. J. Neurorestoratology 2017, 5: 111-115.
DOI Google Scholar
[2]
Huang KL, Marcora E, Pimenova AA, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat Neurosci. 2017, 20(8): 1052-1061.
DOI Google Scholar
[3]
Gosselin D, Skola D, Coufal NG, et al. An environment- dependent transcriptional network specifies human microglia identity. Science 2017, 356(6344): eaal3222.
DOI Google Scholar
[4]
Kaluski S, Portillo M, Besnard A, et al. Neuroprotective functions for the histone deacetylase SIRT6. Cell Rep. 2017, 18(13): 3052-3062.
DOI Google Scholar
[5]
Lodato MA, Rodin RE, Bohrson CL, et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 2017, doi: 10.1126/ science.aao4426.
DOI Google Scholar
[6]
Shi Q, Chowdhury S, Ma R, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med. 2017, 9(392): eaaf6295.
DOI Google Scholar
[7]
Sprecher KE, Koscik RL, Carlsson CM, et al. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 2017, 89(5): 445-453.
DOI Google Scholar
[8]
Essuman K, Summers DW, Sasaki Y, et al. The SARM1 toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron 2017, 93(6): 1334-1343.
DOI Google Scholar
[9]
Galindo R, Banks Greenberg M, Araki T, et al. NMNAT3 is protective against the effects of neonatal cerebral hypoxia- ischemia. Ann Clin Transl Neurol. 2017, 4(10): 722-738.
DOI Google Scholar
[10]
Xu H, Cao Y, Yang X, et al. ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery. Blood 2017, 130(1): 11-22.
DOI Google Scholar
[11]
Milosevic L, Kalia SK, Hodaie M, et al. Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson’s disease. Brain 2017, doi: 10.1093/brain/awx296.
DOI Google Scholar
[12]
Harting MT, Srivastava AK, Zhaorigetu S, et al. Inflammation- stimulated mesenchymal stromal cell-derived extracellular vesicles attenuate inflammation. Stem Cells 2017, doi: 10.1002/ stem.2730.
DOI Google Scholar
[13]
Horwitz EM, Le Blanc K, Dominici M, et al. International society for cellular therapy. clarification of the nomenclature for MSC: The international society for cellular therapy position statement. Cytotherapy 2005, 7(5): 393-395
DOI Google Scholar
[14]
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4): 315-317.
DOI Google Scholar
[15]
Galipeau J, Krampera M, Barrett J, et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 2016, 18(2): 151-159.
DOI Google Scholar
[16]
Arjmand B, Safavi M, Heidari R, et al. Concomitant transurethral and transvaginal-periurethral injection of autologous adipose derived stem cells for treatment of female stress urinary incontinence: A phase one clinical trial. Acta Med Iran 2017, 55(6): 368-374.
Google Scholar
[17]
Numan MT, Kamdar A, Young J, et al.. Autologous adipose stem cell therapy for autonomic nervous system dysfunction in two young patients. Stem Cells 2017, 26(6): 391-393.
DOI Google Scholar
[18]
Vaquero J, Hassan R, Fernández C, et al. Cell therapy as a new approach to the treatment of posttraumatic syringomyelia. World Neurosurg. 2017, 107: 1047
DOI Google Scholar
[19]
Vaquero J, Zurita M, Rico MA, et al. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy 2017, 19(3): 349-359.
DOI Google Scholar
[20]
Nguyen LT, Nguyen AT, Vu CD, et al. Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial. BMC Pediatr 2017, 17(1): 104.
DOI Google Scholar
[21]
Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): A randomised, double-blind, placebo- controlled, phase 2 trial. Lancet Neurol. 2017, 16(5): 360-368.
DOI Google Scholar
[22]
Osanai T, Houkin K, Uchiyama S, et al. Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design. Int J Stroke. 2017, 1747493017743057.
DOI Google Scholar
[23]
Liu Y, Chen SJ, Li SY, et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Stem Cell Res Ther. 2017, 8(1): 209.
DOI Google Scholar
[24]
Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell–derived retinal cells for macular degeneration. N Engl J Med 2017, 376: 1038-1046.
DOI Google Scholar
[25]
Huang H, Raisman G, Sanberg PR, et al. Neurorestoratology. New York, Nova Biomedical. 2015.
[26]
Meng J, Zhang S, Bekyo A, et al. Noninvasive Electroencephalogram based control of a robotic arm for reach and grasp tasks. Sci Rep. 2016, 6: 38565.
DOI Google Scholar
[27]
Gao Q, Dou L, Belkacem AN, et al. Noninvasive electroencephalogram based control of a robotic arm for writing task using hybrid BCI system. Biomed Res Int. 2017, 8316485.
DOI Google Scholar
[28]
Nilakantan AS, Bridge DJ, Gagnon EP, et al. Stimulation of the posterior cortical-hippocampal network enhances precision of memory recollection. Curr Biol. 2017, 27(3): 465-470.
DOI Google Scholar
[29]
Mignardot JB, Le Goff CG, van den Brand R, et al. A multidirectional gravity-assist algorithm that enhances locomotor control in patients with stroke or spinal cord injury. Sci Transl Med. 2017, 9(399): eaah3621.
DOI Google Scholar
[30]
Thibaut A, Wannez S, Donneau AF, et al. Controlled clinical trial of repeated prefrontal tDCS in patients with chronic minimally conscious state. Brain Inj. 2017, 31(4): 466-474.
DOI Google Scholar
[31]
Xia X, Bai Y, Zhou Y, et al. Effects of 10 Hz repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in disorders of consciousness. Front Neurol. 2017, 8: 182.
DOI Google Scholar
[32]
Estraneo A, Pascarella A, Moretta P, et al. Repeated transcranial direct current stimulation in prolonged disorders of consciousness: A double-blind cross-over study. J Neurol Sci. 2017, 375: 464-470.
DOI Google Scholar
[33]
Yamamoto T, Watanabe M, Obuchi T, et al. Spinal cord stimulation for vegetative state and minimally conscious state: Changes in consciousness level and motor function. Acta Neurochir Suppl. 2017, 124: 37-42.
DOI Google Scholar
[34]
Chudy D, Deletis V, Almahariq F, et al. Deep brain stimulation for the early treatment of the minimally conscious state and vegetative state: Experience in 14 patients. J. Neurosurg. 2017, 16: 1-10.
DOI Google Scholar
[35]
Carlsson CA, Sundin T. In a paraplegic child. Rev Surg. 1967, 24(1): 73-76.
Google Scholar
[36]
Mohamed A, Omi E, Honda K, et al. Outcome of different facial nerve reconstruction techniques. Braz J Otorhinolaryngol. 2016, 82(6): 702-709.
DOI Google Scholar
[37]
Zhong W, Zhang W, Yang M, et al. Impact of diabetes mellitus duration on effect of lower extremity nerve decompression in 1,526 diabetic peripheral neuropathy patients. Acta Neurochir (Wien) 2014, 156(7): 1329-1333.
DOI Google Scholar
[38]
Yang W, Porras JL, Xu R, et al. Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome. Neurosurgery 2016, 63(Suppl 1): 178.
DOI Google Scholar
[39]
Egashira Y, Yamauchi K, Enomoto Y, et al. Disruption of cortical arterial network is associated with the severity of transient neurologic events after direct bypass surgery in adult moyamoya disease. World Neurosurg. 2017, 100: 311-315.
DOI Google Scholar
[40]
Williamson RW, Abla AA, Zabramski JM, et al. Revascularization of moyamoya angiopathy in older adults. World Neurosurg. 2017, 99: 37-40.
DOI Google Scholar
[41]
Nandra KS, Harari M, Price TP, et al. Successful reinnervation of the diaphragm after intercostal to phrenic nerve neurotization in patients with high spinal cord injury. Ann Plast Surg. 2017, 79(2): 180-182.
DOI Google Scholar
[42]
Bertelli JA, Ghizoni MF. Nerve transfers for restoration of finger flexion in patients with tetraplegia. J Neurosurg Spine 2017, 26(1): 55-61.
DOI Google Scholar
[43]
Medina J, Marcos-García A, Jiménez I, et al. Biceps to triceps transfer in tetraplegic patients: Our experience and review of the literature. Hand (N Y) 2017, 12(1): 85-90.
DOI Google Scholar
[44]
Li F, Wang SF, Li PC, et al. Restoration of active pick-up function in patients with total brachial plexus avulsion injuries. J Hand Surg Eur, doi: 10.1177/1753193417728405.
Google Scholar
[45]
Zheng MX, Hua XY, Feng JT. Trial of contralateral seventh cervical nerve transfer for spastic arm paralysis. N Engl J Med. 2017, doi: 10.1056/NEJMoa1615208.
DOI Google Scholar
[46]
Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017, 376(3): 209-220.
DOI Google Scholar
[47]
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017, 376(3): 221-234.
DOI Google Scholar
[48]
Liu Y, Vollmer T, Havrdova E, et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2017, 11: 18-24.
DOI Google Scholar
[49]
Cohan S, Kappos L, Giovannoni G, et al. Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Mult Scler. 2017, 1352458517735190.
DOI Google Scholar
[50]
Rose JW, Giovannoni G, Wiendl H, et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing- remitting multiple sclerosis. Mult Scler Relat Disord 2017, 17: 32-40.
DOI Google Scholar
[51]
Benedict RH, Cohan S, Lynch SG, et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler. 2017, 1352458517707345.
DOI Google Scholar
[52]
Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017, 16(7): 505-512.
Google Scholar
[53]
Rothstein JD. Edaravone: A new drug approved for ALS. Cell 2017, 171(4): 725.
DOI Google Scholar
[54]
Warner FM, Cragg JJ, Jutzeler CR, et al. Early administration of gabapentinoids improves motor recovery after human spinal cord injury. Cell Rep. 2017, 18(7): 1614-1618.
DOI Google Scholar
[55]
Elkins J, Veltkamp R2, Montaner J, et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): A randomised, placebo-controlled, double- blind phase 2 trial. Lancet Neurol. 2017, 16(3): 217-226.
DOI Google Scholar
[56]
Ono H, Nishijima Y, Ohta S. Hydrogen gas inhalation treatment in acute cerebral infarction: A randomized controlled clinical study on safety and neuroprotection. J Stroke Cerebrovasc Dis. 2017, 26(11): 2587-2594.
DOI Google Scholar
[57]
Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: An efficacious adjuvant therapy for Parkinson’s disease. CNS Neurol Disord Drug Targets 2017, 16(6): 705-713.
DOI Google Scholar
[58]
Juhász A1, Aschermann Z1, Ács P. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: An open- label study. Parkinsonism Relat Disord. 2017, 37: 79-86.
DOI Google Scholar
[59]
Tsai ST, Chu SC, Liu SH, et al. Neuroprotection of granulocyte colony-stimulating factor for early stage Parkinson’s disease. Cell Transplant. 2017, 26(3): 409-416.
DOI Google Scholar
[60]
Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene- replacement therapy for spinal muscular atrophy. N Engl J Med. 2017, 377(18): 1713-1722.
DOI Google Scholar
[61]
Dias MF, Joo K, Kemp JA, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res. 2017, doi: 10.1016/j.preteyeres.2017.10.004.
DOI Google Scholar
[62]
Zhao Y, Tang F, Xiao Z, et al. Clinical study of neuroregen scaffold combined with human mesenchymal stem cells for the repair of chronic complete spinal cord injury. Cell Transplant. 2017, 26(5): 891-900.
DOI Google Scholar
[63]
Huang H, Sun T, Chen L, et al. Consensus of clinical neurorestorative progress in patients with complete chronic spinal cord injury. Cell Transplant. 2014, 23(Suppl 1): S5-S17.
DOI Google Scholar
[64]
Innes KE, Selfe TK, Khalsa DS, et al. Meditation and music improve memory and cognitive function in adults with subjective cognitive decline: A pilot randomized controlled trial. J Alzheimers Dis. 2017, 56(3): 899-916.
DOI Google Scholar
[65]
Song H, Chen X, Yu Y, et al. Xingnao Kaiqiao acupuncture combined with Angong Niuhuang Wan for a patient under persistent vegetative state: A case report. Front Med. 2017, doi: 10.1007/s11684-017-0539-2.
DOI Google Scholar
[66]
Aghayan HR, Arjmand B, Ahmadbeigi N, et al. Draft of Iranian national guideline for cell therapy manufacturing. Arch Iran Med. 2017, 20(8): 547-550.
Google Scholar
[67]
Huang H, Chen L, Zou Q, et al. Clinical cell therapy guidelines for neurorestoration (China version 2016). J Neurorestoratology 2017, 5: 39-46.
DOI Google Scholar
[68]
Feng YP, Sun TS, Chen L, et al. Clinical therapeutic guideline for neurorestoration in spinal cord injury (Chinese version 2016). J Neurorestoratology 2017, 5: 73-83.
DOI Google Scholar
[69]
Xiao J, Chen L, Mao G, et al. Neurorestorative clinical application standards for the culture and quality control of olfactory ensheathing cells. J Neurorestoratology 2017, 5: 175-179.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 25 March 2018
Accepted: 01 June 2018
Published: 29 June 2018
Issue date: December 2018

Copyright

© The authors 2018.

Rights and permissions

© The authors 2018. This article is published with open access at http://jnr.tsinghuajournals.com

Return